Our VP of Chemistry & Early Drug Discovery Matthew Weiss recently published a book chapter on #IRAK4 degraders in #immunology in the American Chemical Society 2024 Medicinal Chemistry Reviews! This exciting overview of the field, which includes our first-in-class oral IRAK4 degrader KT-474, highlights the unique ability of #TPD to unlock this critical pathway. Read more:?https://bit.ly/491wr9q #DrugDiscovery #Chemistry #TargetedProteinDegradation??
Kymera Therapeutics
生物技术研究
Watertown，MA 31,012 位关注者
Inventing a new class of medicines using Targeted Protein Degradation
关于我们
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Kymera is also progressing degrader oncology programs that target undrugged or poorly drugged proteins to create new ways to fight cancer. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years.
- 网站
-
https://www.kymeratx.com
Kymera Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Watertown，MA
- 类型
- 上市公司
- 创立
- 2016
地点
-
主要
获取路线
500 North Beacon Street
4th Floor
US，MA，Watertown，02472
Kymera Therapeutics员工
动态
-
Join our CEO Nello Mainolfi for a fireside chat at the Jefferies London #Healthcare Conference where he’ll discuss our exciting progress, upcoming milestones, and vision to #RevolutionizeImmunology for millions of patients around the world. Listen to the live webcast: https://bit.ly/40H6Y2R #JefferiesHealthcare?
-
-
Don’t miss our CMO Jared Gollob's fireside chats at the Stifel Financial Corp. and Wolfe Research, LLC #Healthcare conferences this week! Learn more: https://bit.ly/3AD5hsQ
-
-
Today our CMO Jared Gollob will discuss our groundbreaking work in #immunology, including what’s ahead for Kymera at the Guggenheim Securities Inaugural #Healthcare Innovation Conference. Listen to the fireside chat webcast here: https://bit.ly/40IvKzI
-
-
Today we thank and honor those who have served by giving back to the New England Center and Home for Veterans. Learn more about this important organization and ways you can get involved: https://nechv.org/? #VeteransDay?
-
#ICYMI Check out our CEO Nello Mainolfi's recent blog on the ground breaking work done by the Kymera team to advance KT-621, our oral #STAT6 degrader with the potential to be a paradigm shifting medicine and change how #Th2 immuno-inflammatory diseases can be treated: https://bit.ly/3YFc523 #RevolutionizingImmunology??
-
Explore our upcoming investor events in November in our latest press release: https://bit.ly/3AjCeKK
-
-
We're #hiring! Join us on our mission to design and deliver transformative degrader therapies with the potential to dramatically improve patients’ lives. Explore our current openings:?https://bit.ly/3Ul93h0 #ReinventingMedicine #Biotech
-
-
Today we shared our third quarter 2024 financial results and highlighted recent company updates and upcoming milestones. Learn more about the progress we’ve made toward building an industry-leading portfolio of degrader medicines with the potential to transform treatment paradigms: https://bit.ly/4hvg6NZ #ReinventingMedicine
-
We’re honored to have received the company #Impact award and the #Leadership award for our CEO Nello Mainolfi at the 7th Annual TPD & Induced Proximity Summit. We’re grateful to be recognized by our peers for our groundbreaking work to advance #targetedproteindegradation to address critical health problems and dramatically improve patients’ lives! #DrugDiscovery #DrugDevelopment?
-